Cite
HARVARD Citation
Rocchi, S. et al. (2021). A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematological oncology. 39 (1), pp. 41-50. [Online].